



Pharmacy Formulary Updates for August 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status August 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO - MA
Koselugo	\$3.65;PA
Tukysa	\$3.65;PA
Pemazyre	\$3.65;PA
Isturisa	\$3.65;PA
Reyvow	\$3.65;PA;QL
Avsola	MB;PA
Oriahnn	\$3.65;PA;QL
Voltaren Arthritis 1% (OTC)	\$3.65;QL
Ubrelvy	\$3.65;PA;QL
Nurtec ODT	\$3.65;PA;QL
Xpovio	\$3.65;PA
Sirturo 20mg	\$3.65;PA

Key

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy